Abstract: One disadvantage of adeno-associated virus (AAV) is low gene expression efficiency due to delayed expression of the inserted gene. Provided is a vector plasmid for producing a vector genome to be inserted into an adeno-associated virus (AAV). The vector plasmid is provided with a vector genome cassette as a template of the vector genome, and the vector genome cassette is provided with: (1) an expression cassette including a nucleic acid molecule encoding a target gene and (b) a nucleic acid molecule encoding an expression regulatory region that allows expression of the target gene; and (2) two nucleic acid molecules positioned on both sides of the expression cassette and encoding inverted terminal repeats (ITRs). Also provided is a pharmaceutical composition containing the AVV vector, for treating or preventing an eye disease or disease associated with same.

Abstract: The present invention provides a micelle comprising an anionic micelle and a protecting agent surrounding the anionic micelle, the anionic micelle being formed from, as a structural unit, an ingredient that has a functional group capable of being anionized under basic conditions and has anionic micelle-forming ability, the protecting agent protecting the anionic micelle. The present invention also provides a micelle comprising a cationic micelle and a protecting agent surrounding the cationic micelle, the cationic micelle being formed from, as a structural unit, an ingredient that has a functional group capable of being cationized under acidic conditions and has cationic micelle-forming ability, the protecting agent protecting the cationic micelle.

Abstract: The present invention provides a micelle comprising an anionic micelle and a protecting agent surrounding the anionic micelle, the anionic micelle being formed from, as a structural unit, an ingredient that has a functional group capable of being anionized under basic conditions and has anionic micelle-forming ability, the protecting agent protecting the anionic micelle. The present invention also provides a micelle comprising a cationic micelle and a protecting agent surrounding the cationic micelle, the cationic micelle being formed from, as a structural unit, an ingredient that has a functional group capable of being cationized under acidic conditions and has cationic micelle-forming ability, the protecting agent protecting the cationic micelle.

Abstract: The use of a granular material which is for orally fast disintegrating tablets and comprises starch and tannic acid allows provision of tablets that can be produced by a simple process with general-purpose production equipment, disintegrate fast and absorbs water in the mouth, and have a proper level of shape retainability for practical use. The present invention also provides a method for producing an orally fast disintegrating tablet, the method comprising compression molding of a granular material for orally fast disintegrating tablets comprising starch and tannic acid, or a mixture of the granular material for orally fast disintegrating tablets and other ingredients (an additive, an active ingredient, and/or the like).

Abstract: The present invention provides a micelle comprising an anionic micelle and a protecting agent surrounding the anionic micelle, the anionic micelle being formed from, as a structural unit, an ingredient that has a functional group capable of being anionized under basic conditions and has anionic micelle-forming ability, the protecting agent protecting the anionic micelle. The present invention also provides a micelle comprising a cationic micelle and a protecting agent surrounding the cationic micelle, the cationic micelle being formed from, as a structural unit, an ingredient that has a functional group capable of being cationized under acidic conditions and has cationic micelle-forming ability, the protecting agent protecting the cationic micelle.

Abstract: The use of a granular material which is for orally fast disintegrating tablets and comprises starch and tannic acid allows provision of tablets that can be produced by a simple process with general-purpose production equipment, disintegrate fast and absorbs water in the mouth, and have a proper level of shape retainability for practical use. The present invention also provides a method for producing an orally fast disintegrating tablet, the method comprising compression molding of a granular material for orally fast disintegrating tablets comprising starch and tannic acid, or a mixture of the granular material for orally fast disintegrating tablets and other ingredients (an additive, an active ingredient, and/or the like).

Abstract: The use of a granular material which is for orally fast disintegrating tablets and comprises at least one kind of water soluble polymer and tannic acid allows production of tablets that can be produced by a simple process with simple production equipment, disintegrate fast in the mouth, and have a proper level of moldability for practical use. The at least one kind of water soluble polymer is preferably selected from the group consisting of povidone, hydroxypropyl cellulose, pullulan, a polyvinyl alcohol-polyethylene glycol graft copolymer and copolyvidone.

Abstract: An object of the invention is to provide a transdermal absorption preparation capable of sustaining the blood morphine concentration at an effective level over at least 48 hours, etc.

Abstract: The present invention provides a method for treating a corneal disease by administering to a patient in need of such treatment an effective amount of ozagrel or a salt thereof.

Abstract: A therapeutic agent for a corneal disease comprising irsogladine or a salt thereof as an active ingredient. The purpose is to find a substance capable of effectively treating/ameliorating a corneal disease which has been increased in the number of cases thereof in recent years and to provide a therapeutic agent for a corneal disease comprising the substance as an active ingredient.

Abstract: An eye drops container including a container body filled with a drug solution along with a pressurized gas and including a valve mechanism discharging a fixed amount of drug solution; a nozzle member coupled with a stem for open operation of the valve mechanism and including a drug solution drop nozzle; an operating member including an operating piece and attached to the container body; a guide member contained in the operating member and guiding the nozzle member in the axial direction; and a ball contained in the guide member. The nozzle member includes an outer flange for suspending a skirt on the lower surface thereof; the guide member includes a ring-like bottom groove into which the forward end of the skirt enters; and the ball falls into the bottom groove in an upright state to block the open operation of the valve mechanism, and falls onto the outer flange in an inverted state to permit the open operation of the valve mechanism.

Abstract: The present invention provides a method for treating a corneal disease by administering to a patient in need of such treatment an effective amount of ozagrel or a salt thereof.

Abstract: It is intended to provide medicines having a higher ocular tension-lowering effect on ocular hypertension and glaucoma. Because of showing an excellent effect of lowering ocular tension, medicines comprising a combination of a prostaglandin compound with an NO-donating compound are useful in treating ocular hypertension and glaucoma.

Abstract: An eye drops container including a container body filled with a drug solution along with a pressurized gas and including a valve mechanism discharging a fixed amount of drug solution; a nozzle member coupled with a stem for open operation of the valve mechanism and including a drug solution drop nozzle; an operating member including an operating piece and attached to the container body; a guide member contained in the operating member and guiding the nozzle member in the axial direction; and a ball contained in the guide member. The nozzle member includes an outer flange for suspending a skirt on the lower surface thereof; the guide member includes a ring-like bottom groove into which the forward end of the skirt enters; and the ball falls into the bottom groove in an upright state to block the open operation of the valve mechanism, and falls onto the outer flange in an inverted state to permit the open operation of the valve mechanism.

Abstract: Disclosed is an eye drop preparation comprising latanoprost, which is characterized in that the degradation of latanoprost in water can be prevented, the adsorption of latanoprost onto a plastic container can be prevented, and therefore the decrease in the latanoprost content can be prevented satisfactorily. The eye drop preparation comprises an eye drop composition comprising the following components (A)-(B) and packed in a plastic container: (A) latanoprost; and (B) a nonionic surfactant.

Abstract: A therapeutic agent for a corneal disease comprising irsogladine or a salt thereof as an active ingredient. The purpose is to find a substance capable of effectively treating/ameliorating a corneal disease which has been increased in the number of cases thereof in recent years and to provide a therapeutic agent for a corneal disease comprising the substance as an active ingredient.

Abstract: An object of the invention is to provide a transdermal absorption preparation capable of sustaining the blood morphine concentration at an effective level over at least 48 hours, etc.

Abstract: The present invention relates to a composition for repairing injured skin containing a saccharide and povidone-iodine. The present invention has the following characteristics: suppresses time-dependent increase of consistency, it is easy to use, it is a soft preparation, and has superior applicability to a deep wounded lesion and a granulation tissue. The composition of the present invention contains 50 to 90% by weight of saccharide, 0.5 to 10% by weight of povidone-iodine, 0.1 to 20% by weight of water and 0.01 to 10% by weight of phospholipid.

Abstract: A therapeutic agent for a corneal disease comprising irsogladine or a salt thereof as an active ingredient. The purpose is to find a substance capable of effectively treating/ameliorating a corneal disease which has been increased in the number of cases thereof in recent years and to provide a therapeutic agent for a corneal disease comprising the substance as an active ingredient.

Abstract: The present invention provides a composition for repairing injured skin containing saccharide and povidone-iodine of the present invention having characteristices of suppressing time-dependent increase of consistency, easy to use, soft preparation, and superior applicability to a deep wounded lesion and a granulation tissue. The composition for repairing injured skin comprises 50 to 90% by weight of saccharide, 0.5 to 10% by weight of povidone-iodine, 0.1 to 20% by weight of water and 0.01 to 10% by weight of phospholipid.